A catalytic stereo- and chemo-selective method for the reduction of substituted aromatics
作者:Fabienne Fache、Stéphan Lehuede、Marc Lemaire
DOI:10.1016/0040-4039(94)02386-p
日期:1995.2
Various substitutedaromatics have been reduced using colloidal ruthenium under H2 pressure with good stereoselectivity (cis/trans up to 60). Interesting chemoselectivities are also observed.
3% (w/w) supported rhodiumnanoparticle (3.0 ± 0.7 nm) catalysts onto commercial ion-exchange resins. Their application to the liquid-phase hydrogenation reaction of CC bonds shows the most active species are obtained under catalytic conditions at room temperature and 1 bar H2. The heterogeneous catalyst shows excellent activity, selectivity and reusability in the hydrogenation reaction of alkenes
描述了在工业离子交换树脂上制备1.3%(w / w)负载的铑纳米颗粒(3.0±0.7 nm)催化剂的干净方法。它们在C C键的液相加氢反应中的应用表明,在室温和1 bar H 2的催化条件下获得的活性最高。在非常不需要的条件下,非均相催化剂在烯烃和取代的芳烃的氢化反应中显示出优异的活性,选择性和可重复使用性。就载体对催化效率的影响讨论了结果。
Synthesis of Substituted Cyclohexenyl-Based β-Amino Acids by Ring-Closing Metathesis
作者:Andrew D. Abell、James Gardiner
DOI:10.1021/ol0266121
日期:2002.10.1
[structure: see text] A versatile ring-closingmetathesis (RCM) approach has been developed for the preparation of cis and trans cyclohexenyl-based beta-amino acids that are either unsubstituted (3) or substituted (10 and 12) at the alpha-position.
A series of N-cycloalkylcarboxamide derivatives of N-benzyl benzenesulfonamides of Formula I are described.
The compounds inhibit β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of β-amyloid. Pharmaceutical compositions and methods of treatment using these compounds are also disclosed.
Cyclic beta-amino acid derivatives as factor Xa inhibitors
申请人:Corte R. James
公开号:US20060074103A1
公开(公告)日:2006-04-06
The present application describes cyclic β-amino acid derivatives or pharmaceutically acceptable salt forms thereof, wherein the central core is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.